Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells
Zhang C, Sun X, Ren Y, Lou Y, Zhou J, Liu M, Li D. Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Cancer Biology & Therapy 2012, 13: 1214-1220. PMID: 22892842, PMCID: PMC3469479, DOI: 10.4161/cbt.21412.Peer-Reviewed Original ResearchConceptsPancreatic cancer cellsCancer cellsPolo-like kinase 1Human pancreatic cancer cellsChemotherapeutic drug gemcitabinePLK1 inhibitorsCombination index analysisKinase 1Pancreatic cancerClinical investigationTherapeutic targetCancer treatmentExpression levelsDrug gemcitabineValuable targetCellsTreatmentInhibitorsProliferationCritical roleInhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration
Peng G, Ren Y, Sun X, Zhou J, Li D. Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration. Biochemical Pharmacology 2012, 83: 1374-1382. PMID: 22382068, DOI: 10.1016/j.bcp.2012.02.008.Peer-Reviewed Original ResearchConceptsEndothelial cellsCell migrationInhibition of farnesyltransferaseTherapeutic targetTumor cellsCancer treatmentEndothelial cell migrationUse of FTIsProtein 1Cancer therapyAngiogenesisPseudopodia formationInhibition of FTaseInhibitors of farnesyltransferaseInhibitionCellsLocalization of EB1Novel insightsPhysiological processesTherapy